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Resumo  
 
O vírus Influenza A pertence à família Orthomyxoviridae sendo responsável por transmitir 
infeções virais agudas do trato respiratório, como a gripe. Este vírus apresenta uma 
distribuição a nível global e uma elevada taxa de transmissibilidade. A gripe afeta 
maioritariamente crianças, idosos e pessoas com o sistema imunitário mais debilitado. 
Apresenta como sintomas, febre, dores de garganta, dores musculares, dores de cabeça, 
tosse, fadiga e sensação geral de desconforto. 
Este vírus normalmente é transmitido por via aérea através de tosse ou de espirros, isto 
porque através destas ações são libertadas partículas que contêm o vírus. Estas partículas 
podem ser inaladas por outras pessoas, infetando as mesmas, acabando por desencadear a 
doença. Outra forma de transmitir a gripe é através do contacto com superfícies 
contaminadas.   
O vírus influenza A apresenta uma forma esférica e contém um envelope viral onde estão 
inseridas duas glicoproteínas, a hemaglutinina e a neuraminidase, e um canal iónico, o M2. O 
genoma viral é composto por RNA de cadeia simples negativa. A hemaglutinina apresenta 
um papel crucial na entrada do vírus para a célula, uma vez que é através da mesma que os 
recetores de acido siálico são reconhecidos e, para além disto, também participa no 
processo de fusão, onde após a diminuição do pH dentro do endossoma sofre uma alteração 
na sua conformação que a leva a expor o péptido de fusão. Por outro lado, a neuraminidase 
participa na libertação do vírus a partir das células infetadas.  
A prevenção e o controlo da transmissão deste vírus passa pelas vacinas e antivirais já 
existentes no mercado. Devido à elevada taxa de mutação do genoma do vírus, o 
tratamento existente no mercado não é eficaz contra os vírus resistentes. É o caso dos 
inibidores da neuraminidase, como o oseltamivir e zanamivir, e os inibidores do canal iónico 
M2, como a amantidina e rimantadina, que impedem que o vírus infete células. Estes 
antivirais já são comercializados, no entanto, têm vindo a ser retirados do mercado devido à 
existência de efeitos secundários graves e pelo facto de os vírus que têm aparecido mais 
recentemente apresentarem mutações resistentes a estes antivirais. Deste modo, é 
importante encontrar novos alvos de ação para combater a infeção por parte do vírus 
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influenza. Uma das hipóteses passa por desenvolver agentes antivirais, que têm a 
capacidade de inibir a fusão membranar entre o vírus e a célula-alvo. Esta estratégia foi 
aplicada com sucesso contra o vírus da imunodeficiência humana (HIV), estando a ser 
alargada para mais vírus envelopados como é o caso do vírus influenza.  
A inibição da fusão das membranas virais e do hospedeiro é uma estratégia que tem vindo a 
ser estudada. Este passo é essencial para a infeção da célula alvo por parte do vírus. Uma vez 
inibido, o vírus perde a capacidade de infectar a célula do hospedeiro, e como consequência 
não ocorre a propagação viral dentro do hospedeiro. 
Nesta dissertação foram estudados três péptidos com potencial para inibir a fusão 
membranar do vírus influenza com a membrana celular. Estes péptidos foram desenhados a 
partir da região CHR da cadeia HA2 da hemaglutinina, que aparenta ser a zona mais 
conservada da proteína. Todos os péptidos derivados dessa região têm a denominação de 
péptidos C ou inibidores de fusão classe I. Portanto, estes péptidos mimetizam a região CHR 
da proteína viral hemaglutinina e ligam-se à região complementar (NHR) também 
pertencente à mesma proteína.  
Os três péptidos em estudo apresentam a mesma sequência peptídica, contundo são 
diferentes entre si em temos de derivatização. A denominação “Influenza” será atribuída à 
sequência peptídica. O primeiro péptido, Influenza-PEG4-Colesterol, apresenta um 
espaçador com quatro unidades de polietilenoglicol que separa a região peptídica e um 
domínio lípido, o colesterol. Este péptido já foi estudado anteriormente por nossos 
colaboradores do Centro Médico da Universidade de Columbia, em Nova Iorque, que 
tambem nos forneceram estes péptidos. Pelos estudos realizados com o péptido foi possível 
concluir que este consegue bloquear a fusão do vírus através da ligação à hemaglutinina e 
posteriormente incapacitando a mesma de alterar a sua conformação, que é um passo 
essencial para a fusão. Os restantes dois péptidos são derivados do Influenza-PEG4-
Colesterol, sendo que um apresenta apenas a cadeia peptídica sem domínio lipídico e o 
outro é constituído por duas cadeias peptídicas e está conjugado com uma molécula de 
colesterol, (Influenza-PEG4)2-Colesterol. Este projeto teve como objetivo estudar a interação 
do péptido Influenza-PEG4-Colesterol e os seus derivados com sistemas modelo de 
biomembranas e igualmente com membranas de algumas células do sangue, 
nomeadamente eritrócitos e linfócitos.  
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A avaliação desta interação foi efetuada através de metodologias de espectroscopia de 
fluorescência. O primeiro ensaio teve como objetivo avaliar se os péptidos interagem com a 
membrana de vesiculas lipídicas de diferentes composições, POPC e de POPC:Colesterol 
(2:1). Esta avaliação é possível uma vez que os péptidos apresentam um ou dois (no caso do 
dímero) resíduos de triptofano na sua constituição e como se sabe, o triptofano apresenta 
fluorescência intrínseca. Esta fluorescência intrínseca é uma ferramenta válida para 
averiguar a inserção dos péptidos nas vesiculas, sendo que à medida que existe uma 
alteração da fluorescência é sinal que o péptido estará mais inserido na membrana. Neste 
caso, através da excitação seletiva dos resíduos de triptofano e deteção da emissão de 
fluorescência dos mesmos, foi possível observar que o dímero apresentou maioritariamente 
melhores resultados, tendo tido valores de Kp superiores aos dos restantes péptidos, tendo 
maior afinidade para vesículas que contêm colesterol.  
Uma vez que estes péptidos apresentam colesterol na sua constituição, têm uma maior 
tendência para formar agregados. Através da sonda ANS que se torna fluorescente quando 
se insere em microambientes hidrófobos, foi possível observar que tanto o Influenza-PEG4-
Colesterol como o (Influenza-PEG4)2-Colesterol agregam em solução. Como já era 
expectável, o péptido que não apresenta nenhuma componente lipídica, não sofre 
agregação. 
De seguida, através de extintores de fluorescência em solução aquosa (acrilamida) e em 
membrana (5NS e 16NS) foi possível determinar a posição do resíduo de triptofano nas 
membranas lipídicas. O péptido que não apresenta nenhum domínio lipídico, apresenta o 
resíduo de triptofano bastante acessível ao ambiente aquoso, o que nos permite explicar a 
não existência de partição das membranas. Os restantes péptidos mostraram estar mais 
inseridos na membrana e por isso, sofreram menos extinção de fluorescência por parte da 
acrilamida.  
A presença do domínio lipídico poderá permitir ao péptido uma maior interação com as 
membranas. De maneira a avaliar esta interação foi utilizada uma sonda sensível ao 
potencial de dipolo das membranas, a sonda di-8-ANEPPS. Inicialmente foram marcados 
lipossomas com esta sonda para testar a interação dos péptidos com os mesmos. Neste 
caso, não foi registada praticamente nenhuma alteração no potencial de dipolo das 
membranas dos lipossomas. De maneira a estudar a interação com células, tanto os 
Broad-spectrum antiviral peptides against respiratory viruses 
 
VII 
 
eritrócitos como os linfócitos foram marcadas com a mesma sonda. Contrariamente ao que 
foi observado com os lipossomas, já houve uma maior interação por parte dos péptidos com 
as membranas das células. O Influenza-PEG4-Colesterol demonstrou ter maior afinidade para 
os eritrócitos a pH 7 e o péptido (Influenza-PEG4)2-Colesterol demonstrou ter uma afinidade 
maior para os linfócitos, também a pH 7. Um estudo realizado neste grupo, para péptidos 
inibidores de fusão para o HIV, o HIVP4 (que é também um dímero com um domínio de 
colesterol) também apresentou uma maior afinidade para linfócitos.  
Resumidamente, o péptido que não tem colesterol não interage com as membranas lipídicas 
através do resíduo de triptofano, nem aparenta agregar em solução aquosa devido a 
ausência de domínio de colesterol. Em relação ao dímero, este apresentou melhores 
resultados na partição e na interação com células. Este péptido foi o que apresentou uma 
melhor afinidade quando presente em ambiente com pH acídico. O facto de este péptido 
apresentar melhores resultados que o monómero poderá demonstrar que a dimerização do 
péptido pode ser fundamental, uma vez que influencia a concentração do péptido ao nível 
da membrana.  
A conjugação de um domínio lipídico, como o colesterol, e a dimerização aparentam ser 
estratégias que aumentam a atividade antiviral dos possíveis inibidores de fusão do 
influenza A.  
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Abstract 
 
Influenza viruses (IV) are major human pathogens responsible for respiratory diseases 
affecting millions of people worldwide and characterized by high morbidity and mortality. 
Infections by influenza can be controlled by vaccines and antiviral drugs. However, this virus 
is constantly under mutations, leading to growing resistance to influenza antivirals currently 
in use. It is urgent to develop new strategies for therapeutics. Influenza hemagglutinin (HA) 
is a potential target for antiviral drugs, because it is a key protein in the initial stages of 
infection. This protein is involved in receptor binding and promotes the (pH-dependent) 
fusion of virus and cell membranes after endocytosis. HA-targeted peptides are expected to 
lead to novel anti-influenza drugs. Cholesterol conjugated HA-derived peptides with anti-
fusion activity against influenza have been previously studied on live virus. In this study, we 
evaluated three HA-derived peptides using fluorescence spectroscopy. Membrane partition 
assays were performed at two different pH values to assess the interaction with 
biomembrane model systems and (Influenza-PEG4)2-Chol presented the highest partition in 
all the conditions. Peptide aggregation was also assessed by the ANS probe. Human blood 
cells were used to evaluate the extent of cell membrane binding, using the dipole potential 
probe di-8-ANEPPS. In this assay the dimer peptide showed to have higher affinity for PBMC 
and the monomer for erythrocytes. Preferential localization of tryptophan in lipid bilayers 
was also assessed, using aqueous-soluble and lipophilic quenchers. It was possible to 
observe that the untagged peptide is at a shallow position. Therefore, the tryptophan 
residue is more accessible to acrylamide and the cholesterol-tagged peptides are more 
inserted in the membranes. In conclusion, cholesterol-tagged peptides and dimerization may 
be used to increase the activity of the peptides. Our results provide new insight into 
molecular interactions between HA-derived peptides and cell membranes, which may 
contribute toward the development of new influenza A virus inhibitors.  
 
Key words: Influenza A, viral fusion inhibitors, peptides, cholesterol-tagging, dimerization  
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Figure 1: Influenza viruses circulating in 2015/2016 and influenza intensity in May 2016, in Europe. 
Bubbles correspond to different countries and the bubble size is indicative of country population. 
Source: Adapted from European Centre for Disease Prevention and Control 
1.1 Influenza viruses 
Influenza viruses (IV) are major human pathogens responsible for respiratory diseases 
affecting millions of people worldwide and characterized by high morbidity and significant 
mortality (Loregian et al. 2014). The high mortality results not only from pneumonia and 
influenza, but also from cardiopulmonary and other chronic diseases that can be 
exacerbated by the virus.  
IV belong to the Orthomyxoviridae family and is classified into three types, A, B and C 
(Hamilton et al. 2012). The three types of influenza viruses differ in host range and 
pathogenicity. Influenza A is the most dangerous, since it infects a large number of warm-
blooded animals (Taubenberger & Morens 2010), being also found in blood circulation more 
often (Figure 1), while influenza B viruses infect almost exclusively humans (Loregian et al. 
2014).  These two types of influenza viruses are responsible for significant morbidity and 
mortality in infants and elderly people (Vanderlinden & Naesens 2014).   
 
 
Influenza virus A (IAV) is considered a serious threat to public health. It causes a high impact 
at the socioeconomic level, due to the seasonal influenza epidemics and influenza 
pandemics. Seasonal flu epidemics normally occur mainly in the winter in temperate climes 
(Taubenberger & Morens 2010) and it is responsible for about 50000 deaths per year (Yang 
et al. 2013). However, pandemics can be more deadly than seasonal flu epidemics. 
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Pandemics occur when the avian influenza A crosses the specie barrier into humans and the 
spread occurs efficiently from human to human (Yang et al. 2013).  
All over the years, pandemics have been demonstrating their impact in world. The “Spanish” 
influenza pandemics that occurred in 1918 still stands as the single most fatal event in 
human history, known for causing the death to 50 million of people (Taubenberger 2006). 
The causative agent was an avian-descended H1N1 virus (Taubenberger & Morens 2010). 
The most recent pandemic occurred in 2009 and it was considered the first influenza 
pandemic of the twenty-first century. It started in Mexico in mid-February. In May the virus 
was already spread into 41 countries and killed 85 persons (Neumann et al. 2009).   
Due to its historical events (Figure 2), influenza A is one of the greatest threats to 
humankind, being compared to other viruses with major impact in human health such as HIV 
and Ebola. These viruses present a higher mortality if untreated, but they lack influenza 
inter-personal transmission or its widespread seasonal distribution, respectively. In a year of 
new pandemic, Influenza has 4 times the total mortality attributed to HIV in the last 30 years 
(Gatherer 2009). 
 
 
Figure 2: Timeline of Human Flu Pandemics 
Where  correspond to major pandemic and  correspond to the appearance of a new influenza 
strain in the human population. Source: National Institute of Allergy and Infectious Disease. 
 
Now it is clear that the influenza pandemics occur at unpredictable intervals. However, there 
are emerging threats of novel pandemic influenza strains spreading in the human 
population. To deal with it, research efforts have been encouraged in order to develop new 
therapies against influenza viruses.  
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Figure 3: Influenza virus structure 
Adapted from (Medina & García-Sastre 2011) 
1.2 Virus structure and replication cycle 
1.2.1 Structure 
The influenza virion is roughly spherical. It is enveloped by a lipid membrane contains two 
glycoproteins – hemagglutinin (HA) and neuraminidase (NA) - and also a small integral 
membrane protein, M2 (Figure 3) (Bouvier & Palese 2008). Influenza A virus comprises 18 
hemagglutinin (Edinger et al. 2014) and 9 neuraminidase subtypes, determined by the 
distinct antigenicity of each of these protein (Medina & García-Sastre 2011).  
Beneath the lipid membrane there is a viral protein named M1, or matrix protein. This 
protein, which forms a shell, gives strength and rigidity to the lipid envelope. Within the 
interior of the virion, one may find the nuclear export protein (NEP) and the 
ribonucleoprotein (RNP) complex, which consists of the viral RNA segments coated with 
nucleoprotein (NP) and the heterotrimeric RNA-dependent RNA polymerase (PB1, PB2 and 
PA) (Bouvier & Palese 2008). The single-stranded, negative-oriented RNA genome is divided 
over eight viral ribonucleoprotein (vRNP) segments (Vanderlinden & Naesens 2014). 
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1.2.2 Replication cycle 
 
The entry process of the virus represents a potential target for drug development. Influenza 
A virus entry is a dynamic process that requires the achievement of six individual steps: 
binding to target cells, internalization into cellular compartments, endosomal trafficking, 
fusion of viral and endosomal membranes, uncoating and importing of the viral genome into 
the nucleus.   
The first step is initiated by the recognition and binding of the receptor sialic acid (N-
acetylneuramic acid) by hemagglutinin (Edinger et al. 2014). After binding, the virus is 
internalized by endocytosis. Influenza A virus is capable of using multiple endocytosis routes, 
which is clear because it was already observed that IAV could internalize mainly into clathrin-
coated but also uncoated vesicles (Sieczkarski & Whittaker 2002). During maturation of the 
endosome, the pH drops from 7 to around 5, leading to a consequent conformational 
change in HA that initializes the fusion of the viral envelope with the endosomal membrane. 
The conformational changes that occur in HA are necessary to expose the fusion peptide 
(Vanderlinden and Naesens 2014)  . Afterwards, it is inserted into the target membrane, 
bringing the viral and endosomal membranes into close proximity, leading to the creation of 
the fusion pore (Hamilton et al. 2012) . After the fusion, occurs the release of the viral RNA 
and viral proteins into the cytosol, through the fusion pore. This process is called uncoating 
and requires coordinated action of the M2 and M1 proteins, where M2 is responsible for the 
pH drops in the endosome by the mediation of proton influx. M2-mediated change in pH is 
required for the detachment of M1 from the viral RNA, resulting in its release to the cytosol 
(Edinger et al. 2014). The viral RNA traffics to the nucleus, where the viral polymerase starts 
mRNA synthesis and therefore its mRNA transcription is initiated. Newly formed viral RNAs 
are exported to the cytosol, where they assemble with new virus structural proteins, which 
are processed in the endoplasmic reticulum (ER) and the Golgi apparatus and subsequently 
transported to the cell membrane. As the vRNPs reach the cell membrane, they associate 
with viral glycoproteins at the plasma membrane from which new virions bud off. At last, NA 
cleaves the sialic acid termini on viral and cell membrane glycoproteins achieving the release 
of new virions from the host cell (Figure 4) (Das et al. 2010).   
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Figure 4: Schematic diagram of the influenza viral life cycle. 
(Neumann et al. 2009) 
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1.3 Transmission of influenza virus  
  
Transmission of an infectious disease is the process by which an infectious organism moves 
from one host to another and causes disease (Killingley & Nguyen-Van-Tam 2013). Limited 
understanding of influenza transmission has been a frequent obstacle during the 
development of pandemic influenza infection prevention.  
The entry and exit of the virus in humans occur through the respiratory tract, that is, mouth 
and nose. Viruses are released from an infected host during events such as coughing, 
sneezing and talking. After these events, the virus is able to entry in a new host via 
inhalation or direct and indirect contact (Killingley & Nguyen-Van-Tam 2013). 
There are a huge number of factors that may contribute to an effective or a non-effective 
transmission of the influenza virus, as we can see in figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Factors that affect influenza transmission. 
(Killingley & Nguyen-Van-Tam 2013) 
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However, three routes of influenza transmission are widely accepted, namely:  
 Aerosols: these particles are small enough to be inhaled (<5 µm) and reach the lower 
respiratory tract (Cowling et al. 2013). 
 Droplets: these particles can deposit on mucous surfaces of the upper respiratory 
tract such as the mouth and nose. They can be inhaled but are too large (>10 µm) to 
reach the lungs (Willem et al. 2012).  
 Contact transmission: particles are transferred to mucous membranes of the upper 
respiratory tract either directly or indirectly, via a contaminated object or person, 
(Herfst et al. 2012).  
 
Moreover, in order for the viruses to cause an infection, they must survive in the 
environment and reach the target cells in a host and finally, enough virus must reach its 
target cells to achieve an infectious dose to initiate the infection (Killingley & Nguyen-Van-
Tam 2013).  
Understanding how and why the viruses spread so efficiently among people and determining 
possible ways to harness this transmission have been arduous tasks, given the limitations of 
flu animal models (Lakdawala & Subbarao 2012). This knowledge is crucial to the 
development of new and effective ways to prevent the transmission of this virus.   
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Figure 6: Influenza virus vaccine production process. 
(Krammer & Palese 2015) 
1.4  Prevention and control  
 
Influenza infections can be controlled by vaccination and antiviral drugs (Neumann et al. 
2009; Loregian et al. 2014).  
Vaccines give limited protection and need annual updating, due to antigenic drift. Antigenic 
drift is a mechanism for variation in viruses that involves the accumulation of mutations 
(Krammer & Palese 2015). This results in a new strain of virus particles, which cannot be 
inhibited as effectively by the antibodies, as they were originally targeted against previous 
strains, making it easier for the mutant virus to spread throughout a partially immune 
population. 
There are two major problems relating to pandemic influenza vaccines: the time between 
virus identification and vaccine development and distribution (Figure 6), and the weak 
immune responses (low immunogenicity) (Krammer & Palese 2015).  
Rapid vaccine production is vital for reducing global morbidity and mortality. The production 
of a vaccine against a newly emerging strain would take about 7 – 8 months, enough time 
for a virus to spread globally and substantially strain health care systems and global 
economy. 
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At present, influenza is the only respiratory virus against which antiviral drugs are 
commercially available (Heikkinen 2016). The available drugs include the neuraminidase (NA) 
inhibitors oseltamivir (oral administration) and zanamivir (administration by inhalation); and, 
M2 ion channel blockers, such as amantadine and rimantadine (Skalickova et al. 2015). For 
young children, oseltamivir is the only option (Heikkinen 2016). 
Although ion channel inhibitors can be effective against influenza virus infection, they have 
been reported to cause central nervous system side effects. Also, the currently circulating 
influenza strains are resistant to these antivirals that block the ion channel formed by M2. In 
case of the neuraminidase inhibitors, they interfere with NA enzyme activity, which is critical 
for the release of newly synthesized virus from infected cells (Yang et al. 2013). However, 
the currently available drugs suffer from rapid and extensive emergence of drug resistance, 
due to the resistant viruses that are constantly emerging.  
Several new classes of antiviral agents targeting viral replication mechanisms or cellular 
proteins/processes are under development (Loregian et al. 2014). 
All of this highlights the urgent need for developing new antiviral strategies with novel 
mechanisms of action and with reduced drug resistance potential. 
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1.5 Hemagglutinin (HA) 
 
Hemagglutinin is the viral protein that mediates the entry of influenza viruses into host cells. 
This protein controls two critical aspects of entry: virus binding and membrane fusion 
(Hamilton et al. 2012). 
In virion surface, HA is expressed as a trimer. The stalk region of HA 
connects it to the virion envelope by a short hydrophobic sequence 
(Skehel & Wiley 2000). The stability and the structure of this protein 
are afforded by the fact that the stalk region is heavily glycosylated 
on conserved epitopes (Roberts et al. 1993).   
The HA protein contains multiple disulfide bonds and is cleaved into 
a mature form consisting of two subunits, HA1 and HA2. The 
receptor binding pocket (RBP) is located on the distal end of the HA 
trimers, at the globular head, and is highly conserved among 
different HA subtypes (Figure 7). The receptor sialic acid is the major 
point of contact between the virus and the cell and occupies the 
whole RBP. The interaction between the receptor and the protein 
is known to be of low affinity. In order to increase it, multiple HA 
molecules are used to bind several glycoproteins (Edinger et al. 
2014).  
As previously mentioned, at acid pH, the membrane fusion potential of HA is activated in 
endosomes by the induction of an irreversible reorganization of its structure. In figure 8, we 
can see the major change on HA conformation: a dissociation of HA1 from the endosomal 
membrane and its movement away from HA2, a loop-to-α-helix transition in HA2 enables the 
fusion peptide at the N terminus of HA2 to attach to the endosomal membrane and promote 
the fusion of the viral and endosomal membranes, resulting in the release of the viral RNA 
into the cytoplasm (Russell et al. 2008). Small molecules that block this irreversible 
reorganization of HA would be expected to inhibit virus entry.  
 
 
Figure 7: Structure of the HA  
The trimeric complex is shown with 
one monomer highlighted in color. 
Adapted from (Edinger et al. 2014) 
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The hemagglutinin is also known to bind to sialic acid receptor on the surface of red blood 
cells (RBC) and create a network of interconnected RBC’s and virus particles; this process is 
called hemagglutination (Figure 9). The formation of this network depends on the 
concentrations of the virus and RBC’s. This process is used as a method for quantification the 
relative concentration of the virus in the host (Mammen et al. 1995; Fox et al. 2015).  
  
Figure 8: Structure of HA at neutral pH and at fusion pH 
The disulfide-linked polypeptide chains, HA1 and HA2 are 
colored blue and multicolored, respectively. (Russell et al. 
2008) 
Figure 9: Viral Hemagglutination 
Source: Practical Applications of Immunology 
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1.6 Antiviral Peptides against viral fusion 
 
Membrane fusion for viral entry is a key step in viral infectivity, therefore, interference with 
this process can lead to highly effective antivirals. Fusion is driven by specialized proteins 
that undergo a series of conformational changes. They can be classified according to three 
classes of viral fusogenic membrane glycoprotein based on their mechanism of fusion and 
structure organization (Figure 10): 
 Class I fusion proteins: Comprises Influenza A, paramyxovirus F, HIV and Ebola virus. 
All the proteins from this class form homotrimers. Initially, they are synthesized as 
fusion-inactive precursor molecules and, depending on the viral family, can be 
activated in order to expose the N-terminus of the fusion peptide by three ways. The 
first one is by acidic pH, which is the influenza HA case; the second one is by direct 
receptor binding and conjugation with acidic pH  and at least, the activation also can 
occur by the receptor binding by a non-covalently associated envelope glycoprotein 
that stimulates refolding of the fusion protein in neutral pH (Plemper 2011). Class I 
proteins have two heptad repeat (HR) domains, one adjacent to the fusion peptide, 
the N-terminal heptad repeat domain (HRN), and other immediately preceding the 
transmembrane domain, the C-terminal heptad repeat domain (CHR) (Porotto et al. 
2010). The NHR and CHR refolding create the stable six-helical bundle (6HB) 
structure. 6HB formation is linked to the creation of the fusion pore and it is known 
that this structure stimulate the pore formation and expansion (Plemper 2011).  
 
 Class II fusion proteins: Dengue is a virus that contains this type of protein. It is the 
only class that shows a dimeric prefusion conformation, forming an elongated 
structure parallel to the viral envelope. This fusion is triggered by low pH, extending 
the fusion loops towards the target membrane. The final protein structure remains 
rich in β-sheets (Plemper 2011). 
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 Class III fusion proteins: Comprises rhabdovirus and herpesvirus. The protein is a 
trimer in both pre- and postfusion conformations. This fusion is triggered by low pH, 
inducing swinging of the tripod legs towards the target membrane and the postfusion 
structures resembles six-helix bundles of class I proteins, but lacks heptad repeated 
domains (Plemper 2011).  
These three classes of fusion proteins act as functional trimers when driving the membrane 
fusion process and they all fold into stable trimers in the postfusion conformation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Schematic representation of the general domain organization and 
conformational reorganization of the three viral fusion protein classes. 
(Plemper 2011) 
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Understanding the different conformational changes that take place in the three classes of 
fusion proteins is necessary to design fusion inhibitor peptides that can prevent those 
changes during the infection process (Vigant et al. 2015).  Therefore, peptides derived from 
the HR regions, are known to inhibit fusion. These peptides bind to their complementary HR 
region and prevent NHR and CHR from refolding into the stable six-helical bundle (6HB) 
structure required for fusion initiation (Porotto et al. 2010).  
The effectiveness of fusion inhibitor peptides relies on the strength of the interaction 
between the peptide and the target protein, on the location of the peptide, which must be 
in close proximity to the target, and on the peptide orientation at the target membrane 
(Porotto et al. 2010). Cholesterol moieties are able to orientate and localize the peptides on 
the target membrane, leading to an strategy that improve pharmacokinetic properties (Lee 
et al. 2011).  
The major challenge in developing fusion inhibitors for influenza virus has been the fact that 
this virus fusion occurs at intracellular locations. One strategy that has been applied is to tag 
the peptide with a lipid moiety. Lipid-tagged peptides may follow the membrane attached 
HA from the cell surface to the site of fusion activation (Lee et al. 2011). 
The peptides used in this Thesis were designed based on HA2 and, in order to overcome the 
intracellular fusion problem, they were tagged with cholesterol. These peptides are 
supposed to inhibit the fusion of influenza by trapping the HA in a transient conformation. 
Studies with Influenza-PEG4-Chol peptide showed that it is possible to prevent the 
progression of fusion (Lee et al. 2011). 
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1.7 Objectives in the context of the state-of-art 
 
At low pH, the hemagglutinin of influenza virus undergoes an irreversible conformational 
change that potentiates its essential membrane fusion function. Inhibiting this 
conformational change has been the key for the development of new fusion inhibitor 
peptides against all the virus containing hemagglutinin in their composition and had a similar 
fusion process, in order to develop a broad-spectrum anti-fusion peptide.  
Influenza-PEG4-Chol was already studied against live viruses. It was found that this peptide 
was able to trap HA in a transient intermediate state after fusion triggering and before 
completion of the refolding steps that drive the merging of the membranes (Lee et al. 2011). 
Therefore, Influenza-Untagged and (Influenza-PEG4)2-Chol were derived from this peptide, in 
order to evaluate the activity of the peptide without a lipid moiety or with two peptide 
chains, respectively.  
Information obtained on previous studies at Nuno Santos Lab, Biomembrane Unit, at IMM, 
Lisbon, Portugal, with fusion inhibitor peptides against HIV, such as enfuvirtide (Matos, 
Castanho, et al. 2010), C34, C34-Chol (Augusto et al. 2014), sifuvirtide (Matos, Freitas, et al. 
2010) and T-1249 (Matos, Castanho, et al. 2010), shows that their interaction with 
membranes was a significant point to characterize and understand the mechanism of action 
of these peptides. Therefore, for the fusion inhibitor peptides against influenza virus, the 
same principle was applied. The aim of this thesis was to study the interaction between 
Influenza-Untagged, Influenza-PEG4-Chol and (Influenza-PEG4)2-Chol with biomembrane 
model systems and human blood cells. 
Fluorescence spectroscopy methodologies were used to characterize this interaction. These 
methods were used to assess the partition coefficient of the peptides with POPC and 
POPC:Chol (2:1) vesicles, and the peptide aggregation, by the ANS probe.  Quenching studies 
with acrylamide (aqueous quencher) and with 5NS and 16NS (lipophilic quenchers) were 
performed to evaluate the in-depth location of the Trp residues at the membrane. Since the 
direct measure of the peptide intrinsic tryptophan fluorescence is useless in cells, the 
fluorescent lipophilic probe di-8-ANEPPS was used as an indirect reporter to evaluate the 
interactions between the peptides and human blood cells (erythrocytes and lymphocytes).  
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2  Materials and Methods 
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Figure 11: Flu peptides sequence 
In this figure are represented the three principal components: amino acid residues sequence, 
polyethylene glycol (PEG) spacer and cholesterol moiety. The tryptophan residues are highlighted 
by blue 
2.1 Materials 
2.1.1 Peptides 
The peptides tested during the experiments for this thesis (Figure 11) were synthesized from 
the HA2 chain of hemagglutinin, which is the most conserved chain. Influenza-Untagged 
(Mw=4265.5 g/mol), Influenza-PEG4-Chol (Mw=4882.5 g/mol) and (Influenza-PEG4)2-Chol 
(Mw=9755.8 g/mol) peptides were obtained on the context of a collaboration project with 
Dr. Matteo Porotto and Prof. Anne Moscona (Departments of Pediatrics, Microbiology & 
Immunology, and Physiology & Cellular Biophysics at Columbia University Medical Center, 
New York, USA). Stock solutions of each peptide were prepared in dimethylsulfoxide 
(DMSO), with a final concentration of 500 µM, and stored at -20°C.  
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2.1.2 Biological Material 
Human blood samples were obtained from healthy volunteer donors, with their previous 
written informed consent, at Instituto Português do Sangue (IPS), Lisbon. Samples were 
collected to K3EDTA anticoagulant tubes (Vacuette, Greiner Bio-One, Kremsmünster, 
Austria). This study was approved by the Joint Ethics Committee of Faculdade de Medicina 
da Universidade de Lisboa and Hospital de Santa Maria (Lisbon).   
 
2.1.3 Other reagents 
POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocoline) was purchased from Avanti Polar 
Lipids (Alabaster, AL, USA). NaCl, L-tryptophan, DMSO, sodium citrate, chloroform, and 
acrylamide were from Merk (Darmstadt, Germany). HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesufonic acid), cholesterol, Pluronic-F127, ANS (8-anilino-1-
naphthalenesulfonic acid), 5NS (5-doxyl-stearic acid) and 16NS (16-doxyl-stearic acid) were 
acquired from Sigma-Aldrich (St. Louis, MO, USA). The fluorescence probe di-8-ANEPPS (4-[2-
[6-(dioctylamino)-2-naphthalenyl]ethenyl]1-(3-sulfopropyl)-pyridinium) was purchased from 
Invitrogen – Molecular Probes (Eugene, OR, USA). LymphoprepTM was obtained from 
Stemcell Technologies (Vancouver, BC, Canada).  
The working buffers used throughout the studies were HEPES 10mM pH 7.4 with NaCl 
150mM and sodium citrate 10 mM pH 5.0 with NaCl 150mM. L-Tryptophan 500 µM stock 
solution was prepared in buffer, while ANS 2 mM and acrylamide 2 M were prepared in 
ultrapure H2O. Stock solutions of the fluorescence probe di-8-ANEPPS 1 mg/mL and the 
lipophilic quenchers 5NS and 16NS 70 mM were prepared in ethanol. All stock solutions 
were stored at 4˚C, except 5NS and 16NS that were stored at -20˚C.  
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2.2  Methods 
 
2.2.1 Biomembrane  (model) systems preparation  
 
2.2.1.1 Liposomes 
 
Different lipids such as POPC and Chol were weighed to generate vesicles of different 
compositions: pure POPC and POPC:Chol (2:1). To dissolve the phospholipids organic 
solvents such as chloroform were used and mixed in a round-bottom flask. By drying the 
solvent out with a gentle N2 flow, a thin lipid film was formed. To guarantee that solvent 
residues were eliminated and therefore, obtain a completely dried film, the flask was 
connected to a vacuum pump overnight (Esbjörner et al. 2007). In order to form a liposome 
suspension of multilamellar vesicles (MLV), the dried film was hydrated with buffer and then 
8 freeze-thaw cycles were performed. Large unilamellar vesicles (LUV) were obtained by 
extrusion (Mayer et al. 1986) using a mini-extruder (Avanti Polar Lipids, Alabaster, AL, USA), 
1001 RN syringes (Hamilton, Reno, NV, USA) and 100 nm pore polycarbonate 10 nm 
diameter filters (Nucleopore-Whatman, Kent, UK). LUV with, approximately, 100 nm of 
diameter were obtained and used as model system for biological membranes.  
2.2.1.2 Biological Samples  
 
 Erythrocytes isolation 
In order to remove plasma and the buffy-coat (platelets and white blood cells layer 
between erythrocytes and plasma), the blood sample was centrifuged for 10 min at 1200 
g (Sorvall TC6 Centrifuge, H400 rotor). Afterwards, isolated erythrocytes were washed 
three times with working buffer and 100% hematocrit sample was obtained (Matos, 
Freitas, et al. 2010). 
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 Peripheral blood mononuclear cells (PBMC) isolation 
PBMC were isolated by density gradient using LymphoprepTM. The blood samples were 
centrifuged for 30 min at 400 g, allowing the isolation of the buffy-coat containing the 
wanted cells (Matos, Castanho, et al. 2010). Then, isolated PBMC were washed three 
times, with working buffer and, in order to prevent contaminations, an erythrocytes 
lysis buffer (157 mM NH4Cl, 10 mM KHCO3, EDTA 5%, pH 7.4). In the washing steps, 
samples were centrifuged for 5 min at 1500 g. 
 
2.2.2 Partition coefficient determination  
 
Intrinsic peptide fluorescence deriving from the naturally fluorescent amino acid tryptophan 
can provide information on conformational changes (Hawe et al. 2008) and it is a valuable 
tool to quantify their insertion on lipid membranes, such as LUV (Matos, Franquelim, et al. 
2010). The influenza peptides in study contain tryptophan residues (1 residue in the case of 
the Influenza-Untagged and Influenza-PEG4-Cholesterol and 2 residues for (Influenza-PEG4)2-
Cholesterol). The partition coefficient of a molecule between a lipid and an aqueous phase 
can be estimated if a difference occurs in a fluorescence parameter of the partitioning 
molecule or the incorporation of the molecule in the membrane leads to a change on a 
fluorescence property of a membrane probe.  
For each peptide, the partition coefficient can be described as (Matos, Franquelim, et al. 
2010; Santos et al. 2003): 
        𝐾𝑝′ =
ɳ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,𝐿
ɳ 𝐿+ɳ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,𝐿
ɳ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,𝑊
ɳ 𝑤+ɳ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,𝑊
                                                                   (2.1) 
where ɳ 𝐿 and ɳ 𝑊 are the moles of the lipid and water and ɳ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,𝐿 and ɳ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,𝑊 are the 
moles of peptide in lipid and water, respectively. Under most experimental conditions, the 
quantity of peptide is considerably lower in both phases than the total quantities of water or 
lipid (ɳ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,𝑖 << ɳ 𝑖); therefore, this equation can be simplified to: 
        𝐾𝑝′ =
ɳ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,𝐿
ɳ 𝐿
ɳ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,𝑊
ɳ 𝑤
                                                                         (2.2) 
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In most of the literature, it is common to represent the partition coefficient as a function of 
the volumes of each phase (Vi) instead of the water and lipid quantities: 
        𝐾𝑝 =
ɳ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,𝐿
V 𝐿
ɳ 𝑝𝑒𝑝𝑡𝑖𝑑𝑒,𝑊
V 𝑤
                                                                         (2.3) 
This parameter, named the Nernst partition coefficient, can be related with equation (2.4) 
by: 
        𝐾𝑝 = 𝐾′𝑝
𝛾𝑊
𝛾𝐿
                                                                               (2.4) 
Where 𝛾𝑖is the molar volume of water (𝑖 =W) or lipid (𝑖 =L) 
The fluorescence intensity, I, can be measured as long as a peptide fluorescence parameter, 
such as the quantum yield, has a significant difference between the aqueous environment 
and the lipid membrane. 𝐾𝑝 can be determined measuring the tryptophan fluorescence 
intensity with a constant peptide concentration and an increasing lipid concentration ([𝐿]). 
These measurements usually give rise to a hyperbolic I vs [L] variation profile that can be 
fitted using: 
        
𝐼
𝐼𝑤
=
1+ 𝐾𝑝𝛾𝐿
𝐼𝐿
𝐼𝑊
[𝐿]
1+ 𝐾𝑝𝛾𝐿[𝐿]
                                                                         (2.5) 
POPC and POPC:Chol (2:1) were used to assess the peptides membrane partition coefficient. 
Successive additions of a 15 mM LUV suspension to a 5 µM peptide solution in HEPES 10 mM 
in NaCl 150 mM pH 7.4 were done. In case of the partition at pH 5, the working buffer used 
was sodium citrate 10 mM pH5 in NaCl 150 mM. Preceding the fluorescence emission 
analysis, an incubation of 10 min was used after each addition of the LUV suspension. The 
fluorescence emission spectrum of each peptide was recorded between 310 and 450 nm 
using band widths of 5 and 10 nm, respectively and an excitation wavelength (λexc) of 280nm 
was used. The measurements were carried out in a Varian Cary Eclipse Fluorescence 
Spectrophotometer (Mulgarve, Australia) at room temperature. 
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2.2.3 Peptide Aggregation  
 
ANS is an environment sensitive probe. It is essentially non fluorescent in water (low 
quantum yield), becoming fluorescent when bound to hydrophobic sites in proteins (a less 
polar environment), leading to an increase of the quantum yield and it concomitantly 
undergoes a blue shift  (Veiga et al. 2006). For this reason, this probe is commonly used to 
evaluate the presence of hydrophobic pockets in proteins and peptides. Since two of  the 
peptides in study have been conjugated with lipid moieties, they may be prone to 
aggregation in aqueous solution. In order to assess peptide aggregation, the assay was 
followed by ANS fluorescence emission, with excitation at 369 nm, and the fluorescence 
emission was collected between 400 and 600 nm using band widths of 5 and 10 nm for 
excitation and emission, respectively  (Henriques et al. 2008). A solution containing 12.8 µM 
of ANS in HEPES buffer was titrated with a stock solution of the peptide to yield a final 
peptide concentration in the range of 0–8 µM. Measurements were performed in an 
Edinburgh Instruments FLS920 Series fluorescence spectrophotometer (Livingston, UK).  
 
2.2.4 Fluorescence Quenching 
 
Quenching is any process that decreases the fluorescence intensity of a given substance. This 
decrease may be the result of a variety of intermolecular interactions between a fluorophore 
and a quencher, such as energy transfer, ground-state complex formation, molecular 
rearrangements, excited-state reactions or collisional quenching (Lakowicz 2006; Valeur & 
Berberan-Santos 2012).  
There are two types of quenching: the collisional or dynamic and the static one. In both 
cases, molecular contact between the fluorophore and the quencher is required. In the case 
of the collisional quenching, diffusive encounters between the fluorophore and the 
quencher occur during the lifetime of the excited state. Upon contact, the fluorophore 
returns to the ground state, without the emission of a photon (Lakowicz 2006).  
Collisional quenching analysis is generally performed by Stern-Volmer plots whereby the 
fluorescence intensities in the absence and presence of a quencher are collected 
independently and the ratio between these intensities is plotted as a function of quencher 
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concentration, from which Stern-Volmer constant is calculated (Geddes & Lakowicz 2009). 
The Stern-Volmer equation is:  
 
                                  
𝐼0
𝐼
= 1 + 𝐾𝑠𝑣[𝑄]                                                                                    (2.6) 
 
where 𝐼0 and 𝐼 are the fluorescence intensities in the absence and presence of quencher, 
respectively, 𝐾𝑠𝑣 is the Stern-Volmer constant and [𝑄] the concentration of quencher 
(Lakowicz 2006). A high 𝐾𝑠𝑣 would indicate that the fluorophore is efficiently quenched 
whereas a low 𝐾𝑠𝑣 would imply the opposite.  
Static quenching can occur as a result of the formation of a nonfluorescent ground-state 
complex between the fluorophore and the quencher (Lakowicz 2006).  
This has numerous applications for fluorescence quenching studies, these studies may allow 
characterization of conformational changes that alter the accessibility of the fluorophore to 
the quenching agent (Valeur & Berberan-Santos 2012), like we can see in the quenching with 
acrylamide. In this Thesis, it was also possible to perform quenching analysis to evaluate if 
the peptides were (or not) buried in the lipid membrane.  
 
2.2.4.1 Quenching by acrylamide 
 
In order to test the accessibility of the peptides tryptophan residues to the aqueous 
environment acrylamide was used as fluorescence quencher. The emission spectra of 5 µM 
of influenza peptides incubated (or not) with liposomes and in the presence of acrylamide, 
whose concentration ranged from 0-60 mM, were measured in 5 mm x 5 mm path length 
quartz cuvettes (Hellma Analytics, Mulhëim, Germany). The study was done in HEPES buffer 
and in the presence of POPC 2 mM LUV, by the addition of small volumes of the quencher 
stock solution. For every addition, at least a 10 min incubation was allowed before the next 
measurement. In order to promote a selective excitation of tryptophan residues an 
excitation wavelength of 280 nm was used. The measurements were carried out in a Varian 
Cary Eclipse Fluorescence Spectrophotometer (Mulgarve, Australia), at room temperature.  
Data were analyzed by using the Stern-Volmer equation.  
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2.2.4.2 Quenching by 5NS and 16NS 
 
Fluorescence quenching assays with the lipophilic probes 5NS and 16NS were performed by 
time-resolved fluorescence spectroscopy, on a LifeSpec II Fluorescence Lifetime 
Spectrometer (Edinburgh Instruments, Livingston, UK), at room temperature. This is a 
valuable tool to evaluate the depth of insertion in the membrane. Time-resolved intensity 
decays were obtained by pulse excitation at 280 nm and fluorescence acquired at 350 nm 
(20 nm bandwidth) using a 20 ns time span and 1024 channels in a multichannel analyzer.  
In these assays, a 5 µM solution of each peptide was incubated with 3 mM POPC LUV. Then, 
successive additions of small volumes of 5NS or 16NS (in ethanol) were made, keeping the 
ethanol concentration below 2% (v/v) (Yamazaki et al. 1994). The effective concentration of 
the quencher at the membrane level was determined from the partition coefficient of both 
lipophilic molecules to biomembranes (Santos et al. 1998), and ranged from 0 to 
approximately 0.6 M. For every addition, a 10 min incubation time was allowed before 
measurement.  
The fluorescence lifetime values were obtained from intensity decays fits with a sum of 
exponentials, using a nonlinear least-squares method based on the Marquardt algorithm 
(Marquardt 1963). The quality of the fits was evaluated from chi-square (X2), distributions of 
the residuals and autocorrelation plots. In order to obtain the depth of the tryptophan 
insertion in the POPC membrane, the SIMEXDA method (Fernandes, Garcia De La Torre, and 
Castanho 2002) was applied.  
 
2.2.5 Membrane dipole potential assays by di-8-ANEPPS 
 
The membrane has three types of electrostatic potentials: the surface potential, ΨS, 
generated by the charged head-groups of phospholipids and the ions adsorbed at the 
interface, resulting in an accumulation of charges in the outer surface of the membrane; the 
transmembrane potential, ΔΨ, as a result of an imbalance of charge and an electrical 
potential difference across the membrane by selective transport of ions, and therefore, a 
difference in the ion concentration in both sides of the membrane; and the dipole potential, 
Ψd,  which arises from the orientation of lipids dipole residues  (polar head-groups and 
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Figure 12: Electrostatic potentials associated with membranes 
ΨS is the surface potential, ΔΨ is the transmembrane potential and Ψd is 
the dipole potential. Adapted from (Wang 2012). 
glycerol ester regions) and water molecules hydrating the surface of the membrane (Figure 
12) (Matos et al. 2008; Wang 2012; Gross et al. 1994). 
 
 
 
 
 
 
 
 
Changes on the dipole potential can reveal interactions at the membrane level. Such 
alterations may be caused by a destabilization on the lipids organization and/or by the 
contribution of their own dipoles to the membrane dipole potential, caused by 
macromolecules interacting with the membrane. The measure of the dipole potential 
changes is a valuable tool to study the interaction between molecules and the lipid 
membrane, namely for molecules that are not fluorescent. Furthermore, it is not necessary 
to derivatize peptides or proteins, which may modify their structure and, consequently, the 
function and location of these molecules. The influenza fusion inhibitor peptides in study 
have intrinsic fluorescence but, apart from that, they were chemically modified with a 
cholesterol moiety to potentially increase their bioavailability at the membrane level. This 
lipid moiety can interact with the membrane without the involvement of the peptidic region. 
Since the domain that interacts with the membrane is not fluorescent, to monitor changes 
on the membrane properties, the use of a membrane potential-sensitive probe, for instance 
is necessary. In the case of the peptide-cell membrane interaction, this sensitive probe is 
also a useful reporter (Wang 2012). 
Di-8-ANEPPS is the most used probe for measuring dipole potential and allows the 
monitoring of insertion events, as these tend to change the disposition of the molecular 
dipoles of membrane phospholipids (Matos et al. 2008).  
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Figure 13: Structure of di-8-ANEPPS between phospholipids 
Adapted from (Wang 2012) 
 
 
 
 
 
 
 
 
 
This probe has two aliphatic chains (Figure 13), facilitating its incorporation in the outer 
leaflet of the membrane, attached to a chromophore region that stays near the lipid head-
group region and senses the electric fields derived from the dipoles. The changes in the 
dipole are measured in terms of spectral shifts when the probe is incorporated in the lipid 
bilayer. A dual wavelength ratiometric measurement can be carried out, with the benefit of 
the signal being independent of probe or cell concentrations and avoiding photobleaching 
artifacts. In this Thesis, the work conducted with di-8-ANEPPS was based in the 
measurement of the excitation spectrum shifts. Excitation wavelengths of 455 and 525 nm 
were used, with emission set to 670 nm, in order to avoid membrane fluidity artifacts (Clarke 
& Kane 1997; Gross et al. 1994). The variation of the intensities ratio (𝑅 = 𝐼455/𝐼525) with 
peptide concentration can be analyzed by a single binding site model (Cladera & O’Shea 
1998):  
                                                       
                                                                                           (2.7)
 
with the 𝑅 values normalized for the value in the absence of peptide, 𝑅0. 𝑅𝑚𝑖𝑛 is the 
asymptotic minimum value of 𝑅  and 𝐾𝑑 is the dissociation constant. 
 
 peptideK
peptide
R
R
R
R


d
0
min
0
1
Broad-spectrum antiviral peptides against respiratory viruses 
 
31 
 
Figure 14: Representation of membrane dipole potential by di-8-ANEPPS 
The excitation spectrum shifts in response to changes in the dipole potential. The 
differential spectra give a support information to visualize these shifts and to 
determine the wavelengths of maximal variation (Matos, Franquelim, et al. 2010). 
Data can be transformed in differential spectra by subtracting the normalized excitation 
spectra of the probe without the interacting peptide and the spectra in its presence.  
 
 
 
 
 
 
 
 
 
 
 
An increased membrane dipole potential leads to a blue shift in the excitation spectrum, 
resulting in an increased ratio value. On the other hand, a decrease in membrane dipole 
potential leads to a red shift and a consequent decrease on the ratio. If there is no 
interaction between the peptide and the membrane, the dipole potential remains 
unchanged and a shift in the excitation spectra is not expected.  
 
2.2.5.1 Membrane dipole potential of LUV  
 
LUVs were labeled with di-8-ANEPPS, in order to assess membrane dipole potential. To 
maximize the incorporation of the probe in the membrane, a freshly prepared LUV 
suspension containing 500 µM of lipid was incubated overnight with di-8-ANEPPS. Preceding 
fluorescence measurements, each peptide, with concentrations raging from 0 to7 µM, was 
incubated with di-8-ANEPPS-labeled LUV for 1 h at room temperature. An aqueous solution 
of cholesterol (from a DMSO stock solution) was also incubated in the same conditions as 
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the peptides, in order to serve as a control. Excitation spectra and the ratio of intensities at 
the excitation wavelengths of 455 and 525 nm (𝑅 = 𝐼455/𝐼525) were obtained with the 
emission wavelength set to 670 nm. Excitation and emission slits were set to 5 and 10 nm, 
respectively.  
 
2.2.5.2 Membrane dipole potential of erythrocytes  
 
From a previously prepared 10% hematocrit sample, a 1% hematocrit suspension of 
erythrocytes in HEPES buffer supplemented with 0.05% Pluronic F-127 was used for labelling 
with di-8-ANEPPS 10 µM. The suspension with erythrocytes and di-8-ANEPPS was incubated 
with gentle agitation, protected from the light, at room temperature, for 1 h. After this time, 
in order to remove the unbound probe, two wash cycles were performed with 
centrifugations at 1500 g for 5 min. The influenza fusion inhibitor peptides, with a final 
concentration ranging from 0 to 6 µM, were incubated with the labelled erythrocytes for 1 h 
at room temperature and then the fluorescence measurements were performed.  
The experimental conditions of fluorescence measurements were identical to those 
previously described for LUV. 
 
2.2.5.3 Membrane dipole potential of PBMC  
 
PBMC were counted in a Moxi Z Mini automated Cell Counter (ORFLO Technologies, 
Ketchum, ID, USA). A suspension was prepared with a final concentration of 3000 cells/mL in 
0.05% Pluronic F-127 supplemented HEPES buffer with di-8-ANEPPS 3.3 mM. The PBMC 
were incubated with the fluorescent probe suspension at room temperature with gentle 
agitation and protected from the light. The unbound probe was removed by centrifugations 
at 1500 g for 5 min. The peptides were incubated with PBMC at 100 cells/µL during 1 h, 
before the fluorescence measurements. The experimental conditions of fluorescence 
measurements were identical to those previously describe. 
To test the membrane dipole potential of erythrocytes and PBMC at pH 5, sodium citrate 
buffer was used in the finals centrifugations, after the suspension incubation.  
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3  Results and Discussion  
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Figure 15: Partition of the peptides to lipid vesicles 
Membrane partition with POPC vesicles (A) and POPC:Chol (2:1) vesicles (B), in HEPPES buffer 
10mM pH 7.4 
3.1 Partition coefficient determination 
 
Partition into biomembranes is particularly relevant, especially for many molecules that have 
biological membranes as their target (Santos et al. 2003) 
As shown in figure 15 A and B, the peptides tagged with cholesterol had a decrease in the 
fluorescence intensity in the presence of LUV of POPC and POPC:Chol (2:1) at pH 7.4. In the 
case of the Influenza-Untagged peptide, no significant changes were observed, 
demonstrating either an absence of significant peptide-membrane interaction or an 
interaction in which the tryptophan residues are not involved.  
In order to mimic the acidic conditions inside the endosome, the partition assays were also 
performed at pH 5. Figure 16 A and B shows that the (Influenza-PEG4)2-Chol peptide is the 
only one that has a significant decrease in fluorescence intensity either in POPC or 
POPC:Chol vesicles. In this case, not only the untagged peptide but also Influenza-PEG4-Chol 
do not seem to interact with the membrane.  
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Figure 16: Partition of the peptides to lipid vesicles 
Membrane partition with POPC vesicles (A) and POPC:Chol (2:1) vesicles (B), in sodium 
citrate buffer 10mM pH 5 
 
 
 
In order to quantify the extent of interaction of peptides with LUV, the partition coefficient 
between the lipid and aqueous phases was calculated by fitting with Equation 2.5 (Table 1). 
In the case of the untagged peptide, no significant peptide-membrane interactions were 
observed. Previous studies performed for fusion-inhibitory peptides with no lipid moiety or a 
lipid-binding domain also showed no interaction with lipid (Hollmann et al. 2013). Thus the 
absence of interaction between the untagged peptide with the lipid membrane is not 
surprising considering that this peptides primary structure does not include an identifiable 
lipid-binding domain. 
Influenza-PEG4-Chol seems to have a comparable affinity for POPC and POPC:Chol (2:1), as 
similar Kp values were obtained at pH 7.4. When tested for acidic pH the peptide did not 
interact with the membrane composed with either POPC or POPC:Chol (2:1). As mentioned 
before, the hemagglutinin protein at pH 5 undergoes  a conformational rearrangement to 
expose the fusion peptide to the membrane in order to infect the cell (Russell et al. 2008). 
This peptide may suffer an alteration in the tridimensional structure, at pH 5, leading to a 
decrease in the affinity to membranes.   
In the case of the (Influenza-PEG4)2-Chol, it seems to interact with the membrane in all 
conditions tested, as we can see by looking at the Kp values (Table 1). However, the major 
interaction appears to occur with POPC:Chol (2:1) vesicles, at pH 5. As seen before for other 
membrane fusion inhibitor peptides with lipid moieties (Augusto et al. 2014), (Influenza-
PEG4)2-Chol  presented more affinity to cholesterol-rich membranes.  
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Table 1: Partition coefficients of the peptides 
In the cases in which, due to the fact that there are no significant changes in fluorescence intensity, it 
was not possible to fit the equation to calculate the Kp, is considered as approximately 0, and IL/IW is 
represented in the table by (  ̶  ). 
 
           POPC POPC:Chol (2:1) 
 pH Kp IL/IW Kp IL/IW 
Influenza-
Untagged 
7.4 ≈ 0 ̶   ≈ 0 ̶   
5.0 ≈ 0 ̶   ≈ 0 ̶   
Influenza-PEG4-
Chol 
7.4 2692 ± 310 1.04 ± 0.04 2234 ± 569 1.16 ± 0.33 
5.0 ≈ 0 ̶   ≈ 0 ̶   
(Influenza-
PEG4)2-Chol 
7.4 4278 ± 1668 0.95 ± 0.02 1667 ± 383 1.15 ± 0.08 
5.0 4287 ± 1236 0.76 ± 0.06 5119 ± 334 0.83 ± 0.01 
 
 
3.2 Peptide Aggregation - ANS 
 
The peptides conjugated with lipid moieties are prone to self-aggregation when in aqueous 
solutions (Ward et al. 2013). To evaluate the aggregation of these peptides, we used ANS, 
which is an amphiphilic fluorescent probe sensitive to its microenvironment and is 
commonly used to evaluate the presence of hydrophobic pockets in proteins and peptides.  
In this case, for Influenza-PEG4-Chol and (Influenza-PEG4)2-Chol, it was possible to see an 
increase in the fluorescence intensity and a significant blue shift of the maximum 
wavelength of ANS emission (Figure 17), which could indicate the presence of aggregates in 
solution. This happens because the tryptophan residues are in a less polar environment, 
leading to a higher quantum yield (Franquelim et al. 2008).   
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Figure 17: Aggregation of the different peptides: fluorescence properties 
(A) Dependence of fluorescence intensity with peptide concentration; (B) Fluorescence 
spectra that undergo a blue-shift with increasing peptide concentration. ***there are 
significant differences in the data (P<0,001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3 Quenching with acrylamide 
 
In order to test the accessibility of the tryptophan residues of the peptides to the aqueous 
environment, we used acrylamide as a quencher due to its low capacity for penetration into 
lipid bilayers (Franquelim et al. 2008). The fluorescence of the untagged peptide was more 
efficiently quenched in buffer than in the presence of vesicles of POPC (Figure 18 and Table 
2). This might suggest that in the presence of membranes the peptide changes its 
conformation and the Trp residue becomes less prone to suffer quenching by acrylamide. 
It is noticeable that the quenching of the conjugated peptides in buffer is less efficient than 
for the untagged peptide (Table 2), which may indicate that the tryptophan residues are less 
exposed to the aqueous environment.  
 
A 
B 
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Figure 18: Fluorescence quenching by acrylamide 
Quenching in the presence (red) and absence (blue) of POPC vesicles. Continuous lines are fittings 
of the Stern-Volmer equation  
 
In the case of the peptides with cholesterol, there is no significant difference between the 
quenching with or without the presence of lipid vesicles. As these peptides exhibits a high 
tendency to aggregate, the formation those self-assemble structures may be the cause for 
the absence of differences on the exposure of the tryptophan residues to the aqueous 
quencher between the peptides present on the aggregates and those interacting with 
membranes. 
Table 2: Stern-Volmer constants obtained for the quenching of the peptides by acrylamide 
  
3.4 5NS and 16NS Quenching 
 
Accurate determination of the membrane penetration depth is an important step in 
characterizing membrane interactions of proteins and peptides (Ladokhin 2014). 
The in-depth location of the tryptophan residues inserted in lipid membranes was evaluated 
by using the lipophilic quenchers: 5NS and 16NS. The quencher group (doxyl) of these 
molecules, present either on the carbon 5 or the carbon 16 of the fatty acyl chain, when 
inserted in the membrane, has distinct locations: the quencher group of 5NS locates at a 
  Peptides 
System Parameters Influenza-Untagged Influenza-PEG4-Chol (Influenza-PEG4)2-Chol 
Buffer Ksv 19.49 ± 0.63 3.03 ± 0.16 7.94 ± 0.23 
POPC Ksv 7.64 ± 0.19 3.37 ± 0.71 6.36 ± 0.20 
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Figure 19: Fluorescence quenching by 5NS and 16NS, determined by time-resolved fluorescence 
spectroscopy 
Figure 20: Localization of the peptides inside the membrane of POPC 
shallower position, whereas 16NS quencher group locates closer to the hydrophobic core, 
deeply inside the membrane.   
 
In general, 5NS and 16NS were able to assess the tryptophan residues in a similar way, 
suggesting that the tryptophan residues are located in an intermedia position of the 
membrane (Figure 19). 
In order to obtain the in-depth distribution of the fluorophores (Figure 20) the SIMEXDA 
method was applied. This method takes into account the possibility of static quenching by 
using a sphere-of-action methodology (Fernandes, Garcia De La Torre, and Castanho 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
A relatively shallow position is observed for the peptides analyzed. In average, the Influenza-
Untagged is located 17.2 Å away from the center of the bilayer, while Influenza-PEG4-Chol 
and the (Influenza-PEG4)2-Chol were located at 12.4 Å and 13.2 Å, respectively. These results 
are in agreement with acrylamide quenching data, the Influenza-Untagged is at a shallow 
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position and, as we can see at quenching with acrylamide, is the one who’s tryptophan 
residue is more accessible to acrylamide and suffers more quenching. In contrast, Influenza-
PEG4-Chol is the peptide with a deepest insertion in the lipid membrane. This comparison 
should be made, not only looking at the maxima of the distribution (12,4 Å and 13,2 Å), but 
also at the half-widht at half height (Fernandes et al. 2002). For that reason, it is less 
exposed to the aqueous environment and suffers less quenching by acrylamide.  
The inclusion of the PEG4 spacer between the peptide region and the cholesterol moiety may 
contribute to the orientation of the peptide in the membrane, as previously reported 
(Augusto et al. 2014).  
 
3.5 Membrane Dipole Potential  
 
Peptide-membrane interactions were also evaluated using the lipophilic probe di-8-ANEPPS. 
As di-8-ANEPPS is an indirect reporter of the membrane dipole potential, any changes 
caused by the insertion or adsorption of the peptides in/on the membrane can be translated 
in shifts in the probes excitation spectra.  
In the assay with LUV there was a small change in the membrane dipole potential, as we can 
see in the differential spectra (Figure 19). Only the conjugated were able to interact with the 
LUV in order to make a small decrease in the membrane dipole potential of the vesicles.  
Although in the partition assays the cholesterol-conjugated peptides seemed to have a 
major interaction with LUVs, it should be pointed that in those assays only the local changes 
on the tryptophan microenvironment are monitored, whereas the dipole potential changes 
are able to assess the interaction of the whole fusion inhibitor with the membrane. 
In order to quantify the interaction between the peptides and the membranes ratio, R 
(I455/I525, normalized to the initial value), was plotted as function of the peptide 
concentration (Figure 21).  
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Figure 21: Peptides interactions with di-8-ANEPPS labeled LUV of POPC, at pH 7.4. 
(A) Binding profiles of the peptides to LUVs, (B) Differential spectra of di-8-ANEPPS 
bound to LUV 
 
 
 
 
 
 
 
 
 
 
 
In order to have a better understanding of what may happen in the bloodstream, we also 
studied the interaction of these peptides with human blood cells (erythrocytes and PBMC).  
Data show that the conjugated peptides interact with erythrocytes. There was a decrease of 
the membrane dipole potential due to the presence of the peptides (Figure 22). In the case 
of the Influenza-Untagged peptide, there was no interaction until a concentration of 5 µM , 
however in the last concentration (6 µM) it was possible to observe an alteration in the 
membrane dipole. Since hemagglutinin is associated with hemagglutination (Mammen et al. 
1995), this could be the reason for these decrease of the membrane dipole potential, at a 
higher concentration of peptide. 
A 
B 
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Figure 22: Peptides interactions with di-8-ANEPPS labeled erythrocytes, pH 7.4. 
(A) Binding profiles of the peptides to erythrocytes, (B) Differential spectra of di-8-ANEPPS bound to 
erythrocytes 
 
 
 
 
 
 
 
 
 
Similarly, these peptides also interact with PBMCs, as shown in figure 23. In the presence of 
PBMC, the peptides had almost the same behavior as in the presence of erythrocytes: 
conjugated peptides are those presenting a major interaction with the membranes and 
induce a significant decrease in the membrane dipole of PBMC.  
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Figure 23: Peptides interactions with di-8-ANEPPS labeled PBMC, at pH 7.4. 
(A) Binding profiles of the peptides to PBMC, (B) Differential spectra of di-8-ANEPPS bound to 
PBMC 
 
 
 
 
 
 
 
 
 
To assess the behavior of these peptides when they are in an environment with an acidic pH, 
as the case of endosomes, where Influenza is known to fuse, the tracking of changes in the 
membrane dipole potential of blood cell membranes was also performed at these 
conditions. As we can see in figure 24, at pH 5, the conjugated peptides interact both with 
erythrocytes and PBMC. On the contrary, to what we saw for erythrocytes at neutral pH, 
where the untagged peptide seemed to induce hemagglutination, at pH 5 this peptide does 
not have the same behavior. Previously, it was reported that the hemagglutination only 
occur in the pH range of 7-10 (Maeda & Ohnishi 1980). This furthers supports our hypothesis 
of the alteration observed at pH 7.4 being due to hemagglutination.  
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Figure 24: Peptides interactions with di-8-ANEPPS labeled erythrocytes and PBMC, at pH 5. 
 
 
Apparent dissociation constants were determined by fitting the experimental data of the 
conjugated peptides with the equation 2.7 (Table 3). The unconjugated peptide data could 
not be fitted, due to the almost total absence variation of the ratio R as a function of peptide 
concentration. This should be due to a considerably lower interaction of the peptide with 
the blood cells membranes, regardless of the pH value tested, when compared with the 
conjugated molecules, in agreement with the partition data. 
Influeza-PEG4-Chol has a higher affinity (lower Kd) to erythrocytes membranes at neutral pH, 
while (Influenza-PEG4)2-Chol has a higher affinity to PBMC membranes at the same pH. In 
acidic environment, their affinity to blood cells membranes decrease (increased Kd). Only 
Influenza-PEG4-Chol presents just a slight decrease on affinity for PBMC membrane at pH 5. 
As previously reported HIVP4, HIV fusion inhibitor peptide, also has higher affinity towards 
PBMC membrane, with the peculiarity of being  also a dimer (Augusto et al. 2014).    
As common for mammalian cells, erythrocytes and PBMC have cholesterol in their 
membrane composition (Almizraq et al. 2013; Leidl et al. 2008). These cholesterol-
conjugated peptides seem to have a higher affinity with these cells membrane than with the 
POPC vesicles. This reinforces that the peptides may interact preferentially with cholesterol 
containing membranes.  
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Table 3:  Apparent dissociation constants and Rmin values of the peptides for erythrocytes and 
PBMC, at different pH values, calculated fitting the experimental data with equation 2.7 
 
 
Erythrocytes PBMC 
 pH Kd Rmin Kd Rmin 
Influenza-Untagged 
7.4 - - - - 
5 - - - - 
Influenza-PEG4-Chol 
7.4 0.29 ± 0.05 -0.48 ± 0.02 0.56 ± 0.06 -0.56 ± 0.01 
5 2.33 ± 0.45 -0.68 ± 0.05 0.86 ± 0,15 -0.60 ± 0.03 
(Influenza-PEG4)2-Chol 
7.4 0.65 ± 0.13 -0.62 ± 0.03 0.41 ± 0.13 -0.53 ± 0.03 
5 51.34 ± 138 -5.26 ± 12.9 2.23 ± 0.63 -0.65 ± 0.07 
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4  Conclusions 
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In the last few years, the need to overcome resistance has greatly fueled the search for new 
anti-influenza drugs. The targeting of cellular factors involved in the influenza virus 
replication has received much attention because such an antiviral approach could reduce 
viral drug resistance (Loregian et al. 2014).  
The interaction between peptides with lipid membranes is considered relevant for their 
mode of action, once the inhibition process occurs in extreme confinement between the 
cellular plasmatic membrane and the viral envelope (Franquelim et al. 2008). The 
cholesterol-conjugated peptides can interact with the POPC and POPC:Chol membranes. 
By being conjugated with lipid moieties, the peptides are prone to self-aggregation when in 
aqueous solutions, and as we can see with the ANS assay, the cholesterol-tagged peptides 
aggregate more than the untagged peptide.  
The results of the tryptophan residue position showed that the conjugated peptides are 
buried in the membrane and therefore, less exposed to aqueous environment. This explain 
the reason why these peptides suffer less quenching by acrylamide. On the other hand, the 
unconjugated peptide is at a shallow position in the membrane or interacts only with the 
membrane surface, being the tryptophan residue highly exposed to acrylamide. 
In this Thesis, the peptides that have a lipid moiety showed that they are able to interact 
with the membrane of the blood cells in order to alter its dipole potential, as expected. At 
pH 7.4, Influenza-PEG4-Chol presented the highest affinity to erythrocytes membranes and 
(Influenza-PEG4)2-Chol showed the highest affinity to PBMC membranes. However, the same 
was not seen in the assays with acidic pH. The conjugated peptides had higher Kd values in 
these conditions, indicating an affinity decrease with the membranes. At lower pH, the 
deformability of erythrocytes decrease, which indicates that the elastic properties of the 
membrane could be affected by the pH (Kuzman et al. 2000). If the membrane properties of 
the erythrocytes suffer alterations in acidic pH, this could be one of the reasons why these 
peptides had difficulty to interact with it. Peptide binding to blood cells is essential since 
these peptide drugs are expected to circulate in the bloodstream. When administrated, the 
fusion inhibitor peptide can be dissolved into the plasma, bound to the plasma proteins and 
also bound to cell membranes (Matos, Franquelim, et al. 2010).  
From all the assays performed, the conjugated peptides had more activity than the 
unconjugated one. From previous studies, it is known that the majority of the lipid 
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conjugated viral fusion inhibitors have increased potency when compared to unconjugated 
ones (Avadisian & Gunning 2013).  
It has been suggested that the cholesterol conjugation can be useful for viruses that fuse in 
endosomes, by endowing the peptides with the ability to be transfected along with the virus 
to intracellular sites of membrane fusion (Lee et al. 2011). For the conjugated peptides, after 
being able to be included along the virus in the endosome, bound to the outer leaflet of the 
cell membrane (which later becomes the inner leaflet of the endosome membrane), their 
pH-dependent membrane interaction may be an additional advantage. Our membrane 
potential variation data show that the membrane affinity of these molecules decreases upon 
changing from pH 7.4 to pH 5.0. Based on this finding, one may propose that after 
endocytosis, upon the progressive acidification of the endosome, the conjugated peptides 
will progressively be released from the membrane, becoming confined on the volume of the 
endocytic pool. This release of the fusion inhibitor will occur together with the (also) pH-
driven acquiring by hemagglutinin of its fusogenic and fusion inhibitor-targetable extended 
conformation. Therefore, the peptides progressively released from the membrane would be 
able to bind the complementary heptad repeat domain of hemagglutinin, blocking viral 
fusion and the entry of the viral content into the cytosol, therefore preventing the infection 
of a target cell. 
The Influenza-PEG4-Chol peptide was already tested with live virus. It is believed that this 
molecule is able to prevent fusion by blocking the second critical conformation change that 
drives the membranes together (Lee et al. 2011).   
The (Influenza-PEG4)2-Chol peptide showed to have a better membrane affinity as indicated 
in some assays, namely partition data and interaction with PBMC. This is in agreement with 
previous studies where it was reported that dimerization leads to a higher potency and 
activity (Pessi et al. 2012). That study also suggested that dimerization of CHR-derived 
peptide, in conjunction with cholesterol tagging, may be a general strategy for increasing its 
antiviral potency in vitro, and that dimers can be effective in vivo. 
In conclusion, there are three principal components that could improve the antiviral peptide 
activity and potency, the addition of a PEG spacer that enhance their availability (Augusto et 
al. 2014); the cholesterol-conjugation that helps to stabilize the peptide in the membrane 
and increase their half-lives (Johannessen et al. 2011); and dimerization that, as discussed 
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above, also increase the peptide affinity by increasing the quantity of peptide availability in 
the membrane (Pessi et al. 2012). Additionally, as explain above, a pH-sensitive membrane 
interaction may be an advantage for viral fusion inhibitors against viruses which entry occurs 
through an endocytic pathway (such as influenza). In order to design new antiviral peptides, 
this information may be needed to take in account. 
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